PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	J Clin Invest
المؤلفون الرئيسيون:	Panigrahy, Dipak, Singer, Samuel, Shen, Lucy Q., Butterfield, Catherine E., Freedman, Deborah A., Chen, Emy J., Moses, Marsha A., Kilroy, Susan, Duensing, Stefan, Fletcher, Christopher, Fletcher, Jonathan A., Hlatky, Lynn, Hahnfeldt, Philip, Folkman, Judah, Kaipainen, Arja
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	American Society for Clinical Investigation 2002
الموضوعات:	Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC151148/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12370270/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI15634
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!